Daniel Bessesen, MD, Chief of Endocrinology

Adaptive responses to overfeeding and weight regain.

Team: Daniel Bessesen, Emilee Mickaliger, Sheila Steinke 

 

Learn more

Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once weekly in participants with overweight or obesity (NN9838-4608)

Team: Daniel Bessesen, Jeanne Anne Breen, Debbie Bochert, April Hamilton

 

(link to an external website with info on the study?)

Novo 4608 Maintenance Phase

Team: Daniel Bessesen, Jeanne Anne Breen, Debbie Bochert

Team:

A master protocol to investigate the efficacy and safety of LY3437943.